Abstract:…. Translational research regarding these pathogens is focused on developing new strategies to detect, treat and ideally protect humans and animals from these infections. In this Phase I SBIR project, we will establish methodologies for the generation of monoclonal antibodies… more
Abstract:Ricin is a category B toxin due to its ease of acquisition, dissemination, and the high potential for morbidity and mortality after exposure. There are currently no methods of preventing or treating ricin exposure this represents a major unmet need for protection of civilians and warfighters.… more
Abstract:…to antibiotics. The development of novel and effective treatment options are greatly needed improve the safety of the warfighter and general public from these pathogens. The research described in this proposal will lay the foundation for development of antibody based… more
Abstract:… GE2 and administering it chronically to rhesus macaques. In contrast to the immunogenicity observed when human GE2 was injected repeatedly to cynomologus macaques, administration of the homologous proteinwas well-tolerated, producing no adverse events and no anti-GE2 … more
Abstract:… were the first to develop the peptide beacon concept. Based on their work, the University was issued three keyU.S. patents on peptide and DNA beacons. Many AF-mimetic peptides have been discovered and reported in the literature that specifically competes with AF in … more
Abstract:DESCRIPTION (provided by applicant): The goal of this Phase I SBIR is the pre-clinical development of a novel gene-based delivery system for bevacizumab (anti-VEGF antibody) to treat wet age-related macular degeneration (AMD). The premise is based on: (1)the demonstrated… more
Abstract:…veloping biologically active gels that control inflammation by selectively neutralizing pro-inflammatory cytokines based on a technology being licensed exclusively by the company from Carnegie Mellon University. Preliminary results demonstrated that conjugates of antibodies… more
Abstract:Beginning from an advanced stage of development, this Phase II STTR project will produce designs and prototypes for a ricin-specific artificial antibody constructed using DNA origami. These novel constructs will provide both a capture function (mimicking the properties of an… more
Abstract:…a single biothreat agent, the ultimate goal is to advance the Essemblix technology such that, given an epitope for a potential biothreat agent, Essemblix will allow the production of mimotopes that can mimic the original epitope sufficiently to bind target antibodies with high… more
Abstract:…intake and increasing physical activity are often not sustainable and there are few safe alternative treatments. There are no treatments that take advantage of modern molecular medicine's advances in immunotherapy. Therapeutic applications of monoclonal antibodies (mAbs)… more
Abstract:DESCRIPTION (provided by applicant): Topical fluorides have been the mainstay in the prevention of dental caries for decades. However, topical fluoride alone is not enough to thwart tooth decay in high-risk populations. The purpose of this Phase I application is to determine the technical and… more
Abstract:… less than 1mm 1mm footprint. This tiny footprint also enhances sensitivity by orders of magnitude due to their intrinsically low backgrounds currents and UNCD's unique surface chemistry. Finally, UNCD electrode surfaces modified with SAMs, enzymes, antibodies and… more
Abstract:… plasma of healthy and diseased individuals. In order to detect the presence of relevant biomarker levels in the plasma, high affinity highly specific anti-peptide capture reagents must be developed. In this application we propose to develop, high affinity monoclonal … more
Abstract:…f immune responses to enteric pathogens would be advantageous to discovering potential vaccine candidates and defining exposures to enteric infections of interest. Enzyme linked immunosorbent assays (ELISA) are the current"gold standard"to measure serum antibody… more
Abstract:This Small Business Innovation Research (SBIR) Phase II project proposes to develop a new signal amplification system that, while being inexpensive and simple to use, can be combined with antibodies or other probe molecules and can increase detection limits of conventional… more
Abstract:… CD47 on both the leukemia and the host's normal cells, a situation reflecting human cancer therapy. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: CD47 is a cell surface receptor expressed on human leukemia cells. We plan to develop monoclonal antibodies… more
Abstract:… transplantation. However, the founders of Vasculox discovered that thrombospondin-1 (TSP1) binding to its receptor, CD47, limits NO signaling throughout the vascular system thereby worsening IRI. Blocking the TSP1-CD47 system with anti-CD47 monoclonal antibodies (CD47mAbs)… more
Abstract:… (AM) is developing an easy-to-use kit that enables a technician in a life science laboratory to rapidly develop renewable X-Aptamer (XA) affinity reagents at a reasonable price. Affinity reagents are widely used in research, diagnostic, and clinical applications. Antibodies are… more
Abstract:…. The present work continues the drug development of a BBB-penetrating biologic TNFI, which is a re-engineered form of the human type II TNF receptor (TNFR), wherein the TNFR is produced as an IgG fusion protein. The IgG part is a genetically engineered monoclonal antibody… more
Abstract:… work will continue work on the development of a new treatment of the brain of MLD, which is a genetically engineered IgG-enzyme fusion protein. The ASAenzyme is fused to a BBB molecular Trojan horse, which is a genetically engineered peptidomimetic monoclonal antibody… more
Abstract:… circuitry within the brain. To better understand this process requires proteomic approaches, which in turn require better detection reagents for the synapse proteome which comprises over 2,000 different proteins. We propose to use our proprietary yeast display antibody library… more
Abstract:DESCRIPTION (provided by applicant): Monoclonal antibodies targeting tumor associated antigens (TAA's) have since 1997, provided safe and efficacious human cancer therapeutics. More recently, bispecific antibodies or bispecific antibody fragments that promote immunologic… more
Abstract:… receptor-related protein 5 and 6 (LRP5 and 6), are essential for the activation of Wnt pathway. Thus, LRP5/6 becomes an attractive target for developing effective treatments of DR. Through generating and screening a series of mouse anti-human LRP6 monoclonal antibodies… more
Abstract:…he disease (which is particularly important with increasing emphasize on test-and-treat and treatment-as-prevention concepts). Yet another important application is the diagnosis of infection in babies born to HIV-infected mothers since persistent maternal antibody makes… more
There are several categories such as “By Agency”, “By Year”, “By State” etc.
Select a checkbox within a category to refine your search results.
Each of your selections is listed in the “Narrow Search Filters” bar. You can uncheck these selections to remove them.
Search for Either Criteria
When you select multiple values within a category, the results will include values that match either of the selections.
For example, selecting “2005” and “2007” in the “By Year” category will display results that include either 2005 OR 2007 in the results.
Narrowing the Search Results
You can refine your search results across categories. To narrow down your results, select multiple values across different categories. The results will only include values that match the selections across the categories.
For example, selecting “2005” in the “By Year” category and “NASA” in the “By Agency” category will only display the results that contain both “2005” AND “NASA” in the results.